Complete resolution of refractory cutaneous arteritis by intravenous cyclophosphamide pulse therapy

Kawakami, Tamihiro; Okano, Tatsuro; Takeuchi, Sora; Kimura, Satoko; Soma, Yoshinao

doi:10.1111/ijd.12863

Search citation statements

Order By: Relevance

Paper Sections

Select...

Cutaneous Polyarteritis Nodosa1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2022

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Azathioprine (2mg/kg daily) (31) or methotrexate (15-25mg weekly) (35) are commonly used. Patients with severe, painful, ulcerative disease who fail to respond to these agents may respond to therapy with a TNFa inhibitor (36,37), cyclophosphamide (38), or intravenous immunoglobulin (39). In cPAN, ulcerative disease correlates with a relapsing course and the need for more aggressive therapy (40).…”

Section: Cutaneous Polyarteritis Nodosamentioning

confidence: 99%

Treatment of cutaneous vasculitis

Micheletti

2022

Front. Med.

View full text Add to dashboard Cite

Cutaneous vasculitis encompasses a spectrum of disease states, with varied morphology, severity, and potential for systemic involvement. Even vasculitis which is skin-limited can have a significant quality-of-life impact, necessitating treatment. This manuscript summarizes the available evidence for management of various types of skin-limited vasculitis and provides a proposed therapeutic ladder based on published studies and expert opinion.

show abstract